173 related articles for article (PubMed ID: 18535578)
1. Bedside to bench: betting on B cells in multiple sclerosis.
Link H
Nat Med; 2008 Jun; 14(6):615-6. PubMed ID: 18535578
[No Abstract] [Full Text] [Related]
2. Autoimmune diseases. The B cell slayer.
Matthews R
Science; 2007 Nov; 318(5854):1232-3. PubMed ID: 18033858
[No Abstract] [Full Text] [Related]
3. Natalizumab. Elan/Biogen.
Elices MJ
Curr Opin Investig Drugs; 2003 Nov; 4(11):1354-62. PubMed ID: 14758775
[TBL] [Abstract][Full Text] [Related]
4. Treating multiple sclerosis with monoclonal antibodies.
Buttmann M; Rieckmann P
Expert Rev Neurother; 2008 Mar; 8(3):433-55. PubMed ID: 18345973
[TBL] [Abstract][Full Text] [Related]
5. [B lymphocytes: a new "target" in treatment for multiple sclerosis].
Hohlfeld R
Nervenarzt; 2009 Feb; 80(2):147-8. PubMed ID: 19159911
[No Abstract] [Full Text] [Related]
6. Lessons for clinical trials from natalizumab in multiple sclerosis.
Chaudhuri A
BMJ; 2006 Feb; 332(7538):416-9. PubMed ID: 16484271
[TBL] [Abstract][Full Text] [Related]
7. [B cell-directed therapy in rheumatoid arthritis. Multiple management concept?].
Musch A
Med Monatsschr Pharm; 2005 Dec; 28(12):422-5. PubMed ID: 16389869
[No Abstract] [Full Text] [Related]
8. Rituximab and multiple sclerosis.
Kitsos DK; Tsiodras S; Stamboulis E; Voumvourakis KI
Clin Neuropharmacol; 2012; 35(2):90-6. PubMed ID: 22421587
[TBL] [Abstract][Full Text] [Related]
9. Challenges and opportunities: what we are learning from the clinical natalizumab experience.
Kachuck NJ
Expert Rev Neurother; 2005 Sep; 5(5):605-15. PubMed ID: 16162084
[TBL] [Abstract][Full Text] [Related]
10. Humanized anti-CD25 antibody treatment with daclizumab in multiple sclerosis.
Martin R
Neurodegener Dis; 2008; 5(1):23-6. PubMed ID: 18075271
[TBL] [Abstract][Full Text] [Related]
11. More to come: humoral immune responses in MS.
Dobson R; Meier UC; Giovannoni G
J Neuroimmunol; 2011 Dec; 240-241():13-21. PubMed ID: 22019113
[TBL] [Abstract][Full Text] [Related]
12. Immunotoxicity profile of natalizumab.
Wehner NG; Gasper C; Shopp G; Nelson J; Draper K; Parker S; Clarke J
J Immunotoxicol; 2009 Jun; 6(2):115-29. PubMed ID: 19589098
[TBL] [Abstract][Full Text] [Related]
13. Natalizumab for multiple sclerosis?
Drug Ther Bull; 2008 Sep; 46(9):69-72. PubMed ID: 18784381
[TBL] [Abstract][Full Text] [Related]
14. Clinical aspects of serotonin therapy of autoimmune disturbances.
Abramchik GV; Leonovich AL; Ulashchik VS; Starostenko LI; Tanina RM
Hum Physiol; 1984; 10(2):105-9. PubMed ID: 6336211
[No Abstract] [Full Text] [Related]
15. Reply to "'Thinking without thinking' about natalizumab and PML".
Houff S; Berger JR
J Neurol Sci; 2008 Jan; 264(1-2):198-9; author reply 199. PubMed ID: 17936798
[No Abstract] [Full Text] [Related]
16. Rituximab in a patient with multiple sclerosis--effect on B cells, plasma cells and intrathecal IgG synthesis.
Petereit HF; Moeller-Hartmann W; Reske D; Rubbert A
Acta Neurol Scand; 2008 Jun; 117(6):399-403. PubMed ID: 18031564
[TBL] [Abstract][Full Text] [Related]
17. [Update: treatment of multiple sclerosis].
Kümpfel T; Hohlfeld R
MMW Fortschr Med; 2009 Mar; 151(13):70-2. PubMed ID: 19504824
[No Abstract] [Full Text] [Related]
18. Ocrelizumab: A New Therapeutic Paradigm for Multiple Sclerosis
Chin P; Chan AC
Biochemistry; 2018 Feb; 57(5):474-476. PubMed ID: 29172456
[No Abstract] [Full Text] [Related]
19. Long-term B-lymphocyte depletion with rituximab in patients with relapsing-remitting multiple sclerosis.
Stüve O; Leussink VI; Fröhlich R; Hemmer B; Hartung HP; Menge T; Kieseier BC
Arch Neurol; 2009 Feb; 66(2):259-61. PubMed ID: 19204165
[TBL] [Abstract][Full Text] [Related]
20. From translational research to a large randomized clinical trial: a long and streanuous way from bench to bedside.
Sakamoto J; Morita S
Nagoya J Med Sci; 2007 Jan; 69(1-2):9-16. PubMed ID: 17378175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
